Pulmonx Corp. (LUNG): Price and Financial Metrics
LUNG Price/Volume Stats
Current price | $9.27 | 52-week high | $14.84 |
Prev. close | $9.11 | 52-week low | $7.75 |
Day low | $9.12 | Volume | 943,200 |
Day high | $9.46 | Avg. volume | 495,303 |
50-day MA | $11.55 | Dividend yield | N/A |
200-day MA | $11.35 | Market Cap | 357.24M |
LUNG Stock Price Chart Interactive Chart >
LUNG POWR Grades
- Sentiment is the dimension where LUNG ranks best; there it ranks ahead of 68.91% of US stocks.
- The strongest trend for LUNG is in Sentiment, which has been heading up over the past 26 weeks.
- LUNG ranks lowest in Momentum; there it ranks in the 4th percentile.
LUNG Stock Summary
- PULMONX CORP's stock had its IPO on October 1, 2020, making it an older stock than just 12.91% of US equities in our set.
- With a price/sales ratio of 7.1, PULMONX CORP has a higher such ratio than 85.12% of stocks in our set.
- With a year-over-year growth in debt of 67.72%, PULMONX CORP's debt growth rate surpasses 89.05% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to PULMONX CORP are DMTK, TNON, EKSO, ASPN, and SGHT.
- LUNG's SEC filings can be seen here. And to visit PULMONX CORP's official web site, go to pulmonx.com.
LUNG Valuation Summary
- LUNG's EV/EBIT ratio is -7.5; this is 151.37% lower than that of the median Healthcare stock.
- LUNG's price/sales ratio has moved down 33.4 over the prior 39 months.
Below are key valuation metrics over time for LUNG.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
LUNG | 2023-12-29 | 7.5 | 3.9 | -8.0 | -7.5 |
LUNG | 2023-12-28 | 7.7 | 4.0 | -8.2 | -7.7 |
LUNG | 2023-12-27 | 7.7 | 4.0 | -8.2 | -7.7 |
LUNG | 2023-12-26 | 7.7 | 3.9 | -8.1 | -7.6 |
LUNG | 2023-12-22 | 7.5 | 3.9 | -7.9 | -7.5 |
LUNG | 2023-12-21 | 7.5 | 3.9 | -7.9 | -7.5 |
LUNG's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LUNG has a Quality Grade of D, ranking ahead of 6.24% of graded US stocks.
- LUNG's asset turnover comes in at 0.2 -- ranking 142nd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows LUNG's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.200 | 0.720 | -0.626 |
2020-12-31 | 0.206 | 0.648 | -0.660 |
LUNG Price Target
For more insight on analysts targets of LUNG, see our LUNG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $55.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Pulmonx Corp. (LUNG) Company Bio
Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.
Latest LUNG News From Around the Web
Below are the latest news stories about PULMONX CORP that investors may wish to consider to help them evaluate LUNG as an investment opportunity.
Insider Sell: President and CEO French Glendon E. III Sells 10,000 Shares of Pulmonx Corp (LUNG)Pulmonx Corp (NASDAQ:LUNG), a company specializing in medical devices for the treatment of pulmonary disorders, has reported an insider sell according to a recent SEC filing. |
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of DirectorsLOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Se |
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining HealthcareThe article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms. |
Pulmonx to Present at the Piper Sandler 35th Annual Healthcare ConferenceREDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York on Wednesday, November 29, 2023, at 11:00 AM PT / 2:00 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://in |
Pulmonx to Participate at Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 11:25am PT / 2:25pm ET. Interested parties may access a live and archived webcast |
LUNG Price Returns
1-mo | -0.96% |
3-mo | -27.29% |
6-mo | -10.26% |
1-year | -15.50% |
3-year | -78.93% |
5-year | N/A |
YTD | -27.29% |
2023 | 51.25% |
2022 | -73.71% |
2021 | -53.54% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...